AI & DIGITAL ONCOLOGY
Will voice-enabled AI have a role in oncology?
Progress in artificial intelligence tools is opening-up novel modalities to provide education and doctor-patient communication
Will AI reshape breast cancer screening?
While AI tools have shown promise in reducing false positives and aiding radiologists, large prospective trials are now exploring how technology should be integrated in screening programmes
AI is transforming cancer diagnosis, but systemic barriers still hold it back
A new ESMO systematic review maps AI’s growing role in pathology and oncology, as well as challenges in its implementation due to infrastructure, regulatory framework and human factors
LATEST NEWS
Study findings support a growing shift towards “personalised de-escalation” treatment strategies in anal and rectal cancer care
Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers
Tucatinib combo continues to show durable benefit in HER2-mutated metastatic breast cancer
Final data from the SGNTUC-019 trial support the use of the agent with trastuzumab in heavily pretreated patients
Neoadjuvant PD-1 blockade achieves encouraging clinical response in early-stage dMMR tumours
Findings from a small study support a non-surgical and tumour-agnostic approach with immunotherapy, but further research is needed
Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer
Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted antibody-drug conjugate in women receiving at least one prior topoisomerase-1 ADC
TILs show value in predicting relapse risk in TNBC
Retrospective data suggest that patients with low baseline TILs and nodal involvement have poor prognosis despite achieving pathological complete response
Tailored use of chemotherapy may benefit some early-stage ER+/HER2– breast cancers
Results from two studies suggest that withholding chemotherapy for some patients may not impact efficacy, but an understanding of clinical and biological features is paramount
OPINIONS
Shaping the future for young women facing breast cancer
Ann Partridge
Who benefits from immunotherapy for breast cancer?
Sherene Loi
What is the role of adjuvant immunotherapy in contemporary melanoma care?
Marco Donia
Drug de-escalation in lung cancer: are we nearly there yet?
Benjamin Besse
Tumour-agnostic drug development is revolutionising precision oncology
Vivek Subbiah
OPINIONS
Shaping the future for young women facing breast cancer
Ann Partridge
Who benefits from immunotherapy for breast cancer?
Sherene Loi
What is the role of adjuvant immunotherapy in contemporary melanoma care?
Marco Donia
Drug de-escalation in lung cancer: are we nearly there yet?
Benjamin Besse
Tumour-agnostic drug development is revolutionising precision oncology
Vivek Subbiah